Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer

Background: The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) by 38.3 months after treatment with irinotecan, fluorouracil, and leucovorin (FOLFIRI)...

Full description

Bibliographic Details
Main Authors: Jiaqi Han MD, Desheng Xiao PhD, Chongqing Tan PhD, Xiaohui Zeng MD, Huabin Hu MD, Shan Zeng PhD, MD, Qin Jiang MD, Longjiang She MD, Linli Yao MD, Li Li MD, Lanhua Tang PhD, Jian Ma PhD, MD, Jin Huang PhD, MD, Liangfang Shen PhD, MD
Format: Article
Language:English
Published: SAGE Publishing 2020-02-01
Series:Cancer Control
Online Access:https://doi.org/10.1177/1073274820902271

Internet

https://doi.org/10.1177/1073274820902271

Similar Items